Hepatitis B und D: aktuelle und zukünftige Therapien

Translated title of the contribution: Current and Future Therapy of Hepatitis B and D

Frank Tacke

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


With approximately 240 million chronically infected people, hepatitis B virus (HBV) infection is a leading cause of cirrhosis and hepatocellular carcinoma in the world. Chronic HBV infection should be treated with antivirals, if either liver cirrhosis with detectable HBV DNA or relevant viral load (HBV DNA >â€2000â€IU/ml) and signs of liver damage (transaminase elevation, fibrosis, risk of liver cancer or similar) are present. The current standard therapy is a long-term treatment with nucleoside or nucleotide analogues such as entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide, while in selected cases interferon treatment (for 48 weeks) may be useful. Entecavir and the new drug tenofovir alafenamide (TAF) are to be preferred over tenofovir disoproxil fumarate in patients with concomitant renal insufficiency or osteoporosis. Pregnant women with high viral load (>â€200â€000â€IU/ml) should be treated with tenofovir in the third trimester to minimize the risk of neonatal transmission (in addition to immediate active-passive immunization). In conditions of immunosuppression (e.â€g. chemotherapy, rituximab, anti-TNF), even a healed HBV infection may reactivate in a life-threatening manner, requiring prophylactic antiviral therapy in addition to testing for HBV in high-risk situations. The current therapies primarily achieve virus suppression, but rarely the loss of HBs antigen, which is considered a functional cure. New strategies such as discontinuation of long-term antiviral therapy with provoked reactivation and also completely new drugs are currently in clinical trials. The most serious form of viral hepatitis is the co-/superinfection of HBV with the delta virus (HDV). Standard therapy for delta hepatitis is pegylated interferon-alfa, but the approval of new drugs such as the HBV entry inhibitor Myrcludex is expected in the near future.

Translated title of the contributionCurrent and Future Therapy of Hepatitis B and D
Original languageGerman
Pages (from-to)528-534
Number of pages7
JournalDeutsche Medizinische Wochenschrift
Issue number8
StatePublished - 2019
Externally publishedYes


  • delta virus
  • entecavir
  • hepatitis B
  • reactivation
  • tenofovir


Dive into the research topics of 'Current and Future Therapy of Hepatitis B and D: aktuelle und zukünftige Therapien'. Together they form a unique fingerprint.

Cite this